Suppressor Cell-Depleting Immunotherapy with Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis

Shashank Gupta, Laurene Cheung, Supriya Pokkali, Kathryn Winglee, Haidan Guo, John R. Murphy, William R. Bishai

Research output: Contribution to journalArticlepeer-review

Abstract

Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.

Original languageEnglish (US)
Pages (from-to)1883-1887
Number of pages5
JournalJournal of Infectious Diseases
Volume215
Issue number12
DOIs
StatePublished - Jun 15 2017

Keywords

  • Denileukin diftitox recombinant fusion protein toxin
  • Host-directed therapy.
  • Immunotherapy
  • Tuberculosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Suppressor Cell-Depleting Immunotherapy with Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis'. Together they form a unique fingerprint.

Cite this